Skip to main content
Premium Trial:

Request an Annual Quote

RXi Begins Second Phase IIa Trial of Anti-scarring Drug


NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced the start of a Phase IIa trial of its siRNA-based anti-scarring drug RXI-109 for the prevention of keloid recurrence.

RXI-109 comprises siRNAs designed to inhibit connective tissue growth factor, or CTGF, a protein linked to wound healing and other fibrotic processes. It employs the company's proprietary self-delivering technology, which enables cellular uptake without the need for a delivery vehicle.

In the placebo-controlled Phase IIa study, patients with two keloids — a type of scar composed primarily of collagen — of similar size and location are selected for keloidectomy. After the procedure, the lesions will be closed, and one will be treated with RXI-109. Patients will be followed for six months to evaluate the clinical evolution of the lesions.

This latest study follows the initiation of an ongoing Phase IIa trial of RXI-109 in patients with pre-existing hypertrophic scars. These patients undergo scar-revision surgery, after which one end of the scar is treated and the other end receives placebo.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.